MyChesCo on MSN3d
Orchestra BioMed Reports 2024 Financial Results and Advances Cardiovascular Therapy
NEW HOPE, PA — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) has announced its financial results for 2024, alongside major ...
Orchestra BioMed Reports Full Year 2024 Financial Results and Provides a Fourth Quarter Business Update
To accelerate potential completion of ongoing partnership restructuring negotiations, Orchestra BioMed and Terumo have elected to enter a mediation process and are currently working on a procedural ...
Verywell Health7d
7 Common Causes of Pulmonary Arterial Hypertension
Pulmonary arterial hypertension is caused by narrowing of the blood vessels in the lungs. Learn how it happens, including ...
Heart8d
Pacemaker implantation after cardiac surgery: a contemporary, nationwide perspective
Background Cardiac surgery carries a heightened risk of bradyarrhythmias, but current permanent pacemaker (PPM) implantation ...
Taiwan News10d
U.S. Cardiac Resynchronization Therapy Market to Reach $983.3 Million by 2027, Growing at a 4.9% CAGR
The U.S. cardiac resynchronization therapy market was valued at $965.6 million in 2019, and is projected to reach $983.3 million by 2027, registering a CAGR of 4.9% from 2020 to 2027. Surge in ...
Johns Hopkins Medicine24d
Atrioventricular (AV) Canal in Children
What is an atrioventricular canal defect in a child? An atrioventricular (AV) canal defect is a congenital heart defect. This means that your child is born with it. AV canal defect is a large hole in ...